# A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

Study · id `cardio:ct-nct04795531` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04795531](<https://clinicaltrials.gov/study/NCT04795531>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04795531

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 588 participants.

## Technical summary

Registry record NCT04795531. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-24 (actual); primary completion 2022-06-23 (actual). Results posted on 2024-12-04.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 588 participants (enrolled count; ClinicalTrials.gov record NCT04795531, source copy `cardio:ctgov-nct04795531-2026-06-12`, retrieved 2026-11-18)
- Started: 2021-03-24 (actual) (ClinicalTrials.gov record NCT04795531, source copy `cardio:ctgov-nct04795531-2026-06-12`, retrieved 2026-11-18)
- Primary completion: 2022-06-23 (actual) (ClinicalTrials.gov record NCT04795531, source copy `cardio:ctgov-nct04795531-2026-06-12`, retrieved 2026-11-18)
- Completion: 2022-06-23 (actual) (ClinicalTrials.gov record NCT04795531, source copy `cardio:ctgov-nct04795531-2026-06-12`, retrieved 2026-11-18)
- Results first posted: 2024-12-04 (ClinicalTrials.gov record NCT04795531, source copy `cardio:ctgov-nct04795531-2026-06-12`, retrieved 2026-11-18)
- Countries: United States; Argentina; Austria; Brazil; Canada; China; Czechia; Denmark; France; Mexico; Puerto Rico; Taiwan (ClinicalTrials.gov record NCT04795531, source copy `cardio:ctgov-nct04795531-2026-06-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04795531-2026-06-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
- Acronym: ONWARDS 3
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin icodec
- Intervention (Drug): Placebo insulin icodec
- Intervention (Drug): Insulin degludec
- Intervention (Drug): Placebo insulin degludec
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial (`cardio:pubmed-37354562`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8d920934e43dda8a4f7857de9ca6ebb643b1bccaf98c8b78d97f90aca27ce8ea
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
